公司资料
Gilead Sciences 股价、新闻与催化剂
- 股票代码:
- GILD
- 交易所:
- NASDAQ
- 行业:
- Infectious Disease, Biopharma, Nucleic Acid Drugs, CAR-T Therapy, Gene Therapy
- 所在地:
- United States
股票表现
138.92 USD (+0.40%)
收盘价
最后更新: 2026年8月17日
158B USD
市值
股价为何变动
As of Aug 17, 2026, GILD closed up 0.40% at $138.92. No new same-company headline was identified in the current news window.
公司概览
业务概览
Gilead Sciences is a biopharmaceutical company with deep roots in antiviral therapy and growing exposure to oncology and inflammation. Its story has evolved from a legacy antiviral leader into a broader commercial and pipeline platform.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Gilead has a global commercial footprint with major exposure to the U.S. and Europe. It sits in large-cap biopharma with a strong commercial base.
商业模式特征
The company generates revenue through branded therapies, lifecycle management, and pipeline reinvestment across multiple therapeutic areas. Investors focus on HIV, hepatitis, oncology, and the ability to keep replacing mature revenue streams with new assets.
生物医药行业定位
Gilead is a mature large-cap biotech company with enough pipeline depth to retain catalyst sensitivity. It is less binary than development-stage names, but major launch, approval, and partnership updates still matter.
未来催化剂
- Gilead’s biggest near-term catalyst is lenacapavir, especially prevention and filing progress, alongside Trodelvy and the oncology franchise. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。